文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

骨骼健康与更年期:骨质疏松症的预防与治疗。

Bone health and menopause: Osteoporosis prevention and treatment.

机构信息

Mediclinic Panorama and Department of Obstetrics and Gynaecology, Stellenbosch University, South Africa.

出版信息

Best Pract Res Clin Endocrinol Metab. 2024 Jan;38(1):101782. doi: 10.1016/j.beem.2023.101782. Epub 2023 May 9.


DOI:10.1016/j.beem.2023.101782
PMID:37230869
Abstract

A continuous process of bone turnover is central to bone health and strength. If bone resorption exceeds bone formation, bone strength deteriorates with resultant fractures. Osteoporosis is defined by a fracture or bone mineral density. The lack of ovarian estrogen after menopause causes a significant loss in bone strength, placing women at higher risk of osteoporosis. The probability of future fractures can be calculated by identifying risk factors in all menopausal women. Preventive action starts with a bone-friendly lifestyle. The need for and type of interventive medication can best be determined by classifying fracture risk as low, high, or very high using a combination of fracture history, bone mineral density, 10-year fracture probability or country-specific values. As osteoporosis is an incurable disease, treatment should be seen as a lifelong strategy consisting of the correct sequencing of available bone-specific drugs and appropriate drug-free periods when applicable.

摘要

骨转换的持续过程是骨骼健康和强度的核心。如果骨吸收超过骨形成,骨强度就会恶化,导致骨折。骨质疏松症是由骨折或骨密度定义的。绝经后卵巢雌激素的缺乏会导致骨强度显著丧失,使女性面临更高的骨质疏松症风险。通过识别所有绝经后妇女的风险因素,可以计算出未来骨折的概率。预防措施始于一种有益于骨骼的生活方式。通过结合骨折史、骨密度、10 年骨折概率或特定国家的值,将骨折风险分类为低、高或非常高,可最好地确定干预药物的必要性和类型。由于骨质疏松症是一种无法治愈的疾病,因此应将治疗视为一种终生策略,包括正确排列可用的骨特异性药物和在适用时进行适当的无药物治疗期。

相似文献

[1]
Bone health and menopause: Osteoporosis prevention and treatment.

Best Pract Res Clin Endocrinol Metab. 2024-1

[2]
Bone health in women with premature ovarian insufficiency/early menopause: a 23-year longitudinal analysis.

Hum Reprod. 2024-5-2

[3]
Osteoporotic fractures: background and prevention strategies.

Maturitas. 1996-3

[4]
Women's perspectives regarding osteoporosis, fracture risk, and pharmacologic treatment: a cross-sectional study.

Osteoporos Int. 2023-12

[5]
Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.

Ont Health Technol Assess Ser. 2006

[6]
Optimal age for preventing osteoporosis after menopause depends on effects of stopping treatment.

Bone. 2002-5

[7]
Targeting of hormone replacement therapy immediately after menopause.

Bone. 2001-4

[8]
Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.

J Manag Care Pharm. 2012-5

[9]
Pathogenesis, prevention, and treatment of osteoporosis.

Obstet Gynecol. 1990-4

[10]
Bisphosphonates for the prevention and treatment of osteoporosis.

BMJ. 2015-9-2

引用本文的文献

[1]
Synergistic Effects of an Eight-Week Resistance Training and Probiotic Supplementation on Bone Metabolism in Ovariectomized Rats.

Prev Nutr Food Sci. 2025-8-31

[2]
High-efficient discovering the potent anti-Notum agents from herbal medicines for combating glucocorticoid-induced osteoporosis.

Acta Pharm Sin B. 2025-8

[3]
Indigenous women's experiences, symptomology and understandings of menopause: a scoping review.

BMC Womens Health. 2025-8-26

[4]
Yam polysaccharide promoted bone differentiation of MC3T3-E1 cells through targeted Inhibition of CASP3 activation.

J Orthop Surg Res. 2025-8-7

[5]
Set configuration influences cardiovascular responses to resistance exercise in postmenopausal females in a randomized crossover trial from the CARE project.

Sci Rep. 2025-8-4

[6]
Evaluating the risk of osteoporosis-related adverse events with proton pump inhibitors: a pharmacovigilance study.

Front Pharmacol. 2025-7-11

[7]
Biomedical identify the drugs between primary osteoporosis and sarcopenia.

Medicine (Baltimore). 2025-7-11

[8]
Mettl7a alleviated bone loss in osteoporosis mice by targeting the O-GlcNAcylation of Bsp via m6A methylation.

Stem Cells Transl Med. 2025-6-25

[9]
Associations of urinary organophosphate ester metabolites with bone mineral density in U.S. children and adolescents aged 8-19 years: a cross-sectional study based on NHANES 2011-2018.

Eur J Pediatr. 2025-6-4

[10]
Palm Tocotrienol Preserves Trabecular Osteocyte Indices and Modulates the Expression of Osteocyte Markers in Ovariectomized Rats.

Biomedicines. 2025-5-18

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索